Descripción de negocio
Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway™. Formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India.
Consejo de gestión & Consejo de supervisión
| CEO |
| Scott A. Smith |
| Consejo de gestión |
| Sanjeev Narula, Rajiv Malik, Robert J. Coury |
| Consejo de supervisión |
| Robert J. Coury, W. Don Cornwell, JoEllen Lyons Dillon, Elisha W. Finney, Leo Groothuis, Melina Higgins, James Kilts, Harry A. Korman, Rajiv Malik, Richard A. Mark, Mark W. Parrish, Scott A. Smith, Pauline van der Meer Mohr |
Datos de la empresa
| Nombre: |
Viatris Inc. |
| Dirección: |
1000 Mylan Boulevard, Canonsburg,Pennsylvania, 15317, USA |
| Teléfono: |
+1-724-514-1800 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.viatris.com/en |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
Pharmaceuticals |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
16/11/2020 |
